MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Home・Akcijų sąrašas・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.42 5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.4

Max

0.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-15M -35M
Pardavimai	-18M 581K
Pelnas, tenkantis vienai akcijai	-0.11
Pelno marža	-6,012.048
Darbuotojai	183
EBITDA	-15M -33M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+930.95% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-37M 137M
Ankstesnė atidarymo kaina	-4.58
Ankstesnė uždarymo kaina	0.42

Naujienos nuotaikos

By Acuity

50%

151 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.5207 / 0.7223 Palaikymas ir pasipriešinimas

Sangamo Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-30 23:49; UTC

Įsigijimai, susijungimai, perėmimai

WiseTech to Sell Expedient to Appease Competition Regulator

2025-12-30 17:12; UTC

Pagrindinės rinkos jėgos

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

2025-12-30 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-30 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

2025-12-30 21:08; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

2025-12-30 20:41; UTC

Rinkos pokalbiai

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

2025-12-30 20:37; UTC

Uždarbis

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

2025-12-30 19:29; UTC

Rinkos pokalbiai

Corn Extends Pullback in Light Trade -- Market Talk

2025-12-30 18:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

2025-12-30 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-30 16:20; UTC

Uždarbis

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

2025-12-30 16:18; UTC

Įsigijimai, susijungimai, perėmimai

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

2025-12-30 16:10; UTC

Rinkos pokalbiai

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

2025-12-30 15:24; UTC

Rinkos pokalbiai

Australian Dollar Could Rise Versus Sterling -- Market Talk

2025-12-30 15:10; UTC

Įsigijimai, susijungimai, perėmimai

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

2025-12-30 14:24; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

2025-12-30 14:22; UTC

Įsigijimai, susijungimai, perėmimai

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

2025-12-30 14:20; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

2025-12-30 14:17; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

2025-12-30 14:16; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

2025-12-30 14:14; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

2025-12-30 14:12; UTC

Įsigijimai, susijungimai, perėmimai

LVMH: Les Editions Croque Futur Is a French Publishing House

2025-12-30 14:10; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Acquires Les Editions Croque Futur

2025-12-30 13:49; UTC

Įsigijimai, susijungimai, perėmimai

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

2025-12-30 13:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

2025-12-30 13:30; UTC

Rinkos pokalbiai

Crude Futures Gain in Light Holiday Trade -- Market Talk

2025-12-30 12:55; UTC

Rinkos pokalbiai

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

2025-12-30 11:55; UTC

Rinkos pokalbiai

Uždarbis

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

2025-12-30 11:47; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

2025-12-30 11:35; UTC

Įsigijimai, susijungimai, perėmimai

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sangamo Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

930.95% į viršų

12 mėnesių prognozė

Vidutinis 4.33 USD 930.95%

Aukščiausias 10 USD

Žemiausias 1 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sangamo Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Sangamo Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.5207 / 0.7223Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

151 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.